In a recently published meta-analysis, the Nuffield Department of Population Health Renal Studies Group (2022) examined the effects of SGLT2 inhibitors on various outcome measures in patients with CKD with and without type 2 diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.